ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
0 |
19/08/21 |
19/08/21 |
ASX - By Stock
|
4.1K
|
1.9M
|
0
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
3 |
19/08/21 |
19/08/21 |
ASX - By Stock
|
4.1K
|
1.9M
|
3
|
|
ASX - By Stock
|
PAR |
Re:
Chart
|
|
Axlerod
|
4.2K |
3.8M |
16 |
12/08/21 |
12/08/21 |
ASX - By Stock
|
4.2K
|
3.8M
|
16
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
25 |
09/08/21 |
09/08/21 |
ASX - By Stock
|
4.1K
|
1.9M
|
25
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
14 |
03/08/21 |
03/08/21 |
ASX - By Stock
|
4.1K
|
1.9M
|
14
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Trading Halt
|
|
Axlerod
|
318 |
136K |
19 |
02/08/21 |
02/08/21 |
ASX - By Stock
|
318
|
136K
|
19
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Trading Halt
|
|
Axlerod
|
318 |
136K |
11 |
01/08/21 |
01/08/21 |
ASX - By Stock
|
318
|
136K
|
11
|
|
ASX - By Stock
|
PAR |
POST ANNOUNCEMENT DRINKS
|
|
Axlerod
|
24 |
8.1K |
11 |
29/07/21 |
29/07/21 |
ASX - By Stock
|
24
|
8.1K
|
11
|
|
ASX - By Stock
|
PAR |
Re:
real life Zilosul experiences
|
|
Axlerod
|
4 |
1.8K |
3 |
29/07/21 |
29/07/21 |
ASX - By Stock
|
4
|
1.8K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Regulatory Pathways - where we stand with the FDA
|
|
Axlerod
|
74 |
26K |
0 |
29/07/21 |
29/07/21 |
ASX - By Stock
|
74
|
26K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Regulatory Pathways - where we stand with the FDA
|
|
Axlerod
|
74 |
26K |
0 |
29/07/21 |
29/07/21 |
ASX - By Stock
|
74
|
26K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Regulatory Pathways - where we stand with the FDA
|
|
Axlerod
|
74 |
26K |
0 |
29/07/21 |
29/07/21 |
ASX - By Stock
|
74
|
26K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Regulatory Pathways - where we stand with the FDA
|
|
Axlerod
|
74 |
26K |
0 |
29/07/21 |
29/07/21 |
ASX - By Stock
|
74
|
26K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
3 |
28/07/21 |
28/07/21 |
ASX - By Stock
|
4.1K
|
1.9M
|
3
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
0 |
27/07/21 |
27/07/21 |
ASX - By Stock
|
4.1K
|
1.9M
|
0
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
3 |
27/07/21 |
27/07/21 |
ASX - By Stock
|
4.1K
|
1.9M
|
3
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
1 |
27/07/21 |
27/07/21 |
ASX - By Stock
|
4.1K
|
1.9M
|
1
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
4 |
27/07/21 |
27/07/21 |
ASX - By Stock
|
4.1K
|
1.9M
|
4
|
|
ASX - By Stock
|
PAR |
Re:
Where are PAR shareholders located?
|
|
Axlerod
|
115 |
28K |
3 |
27/07/21 |
27/07/21 |
ASX - By Stock
|
115
|
28K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PARADIGM PROVIDES IND APPLICATION UPDATE
|
|
Axlerod
|
103 |
44K |
3 |
27/07/21 |
27/07/21 |
ASX - By Stock
|
103
|
44K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
FDA Meetings
|
|
Axlerod
|
1 |
951 |
0 |
27/07/21 |
27/07/21 |
ASX - By Stock
|
1
|
951
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PARADIGM PROVIDES IND APPLICATION UPDATE
|
|
Axlerod
|
103 |
44K |
0 |
27/07/21 |
27/07/21 |
ASX - By Stock
|
103
|
44K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PARADIGM PROVIDES IND APPLICATION UPDATE
|
|
Axlerod
|
103 |
44K |
0 |
27/07/21 |
27/07/21 |
ASX - By Stock
|
103
|
44K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PARADIGM PROVIDES IND APPLICATION UPDATE
|
|
Axlerod
|
103 |
44K |
1 |
27/07/21 |
27/07/21 |
ASX - By Stock
|
103
|
44K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PARADIGM PROVIDES IND APPLICATION UPDATE
|
|
Axlerod
|
103 |
44K |
0 |
27/07/21 |
27/07/21 |
ASX - By Stock
|
103
|
44K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Likely IND announcement scenarios
|
|
Axlerod
|
15 |
5.8K |
2 |
22/07/21 |
22/07/21 |
ASX - By Stock
|
15
|
5.8K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Likely IND announcement scenarios
|
|
Axlerod
|
15 |
5.8K |
2 |
21/07/21 |
21/07/21 |
ASX - By Stock
|
15
|
5.8K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Likely IND announcement scenarios
|
|
Axlerod
|
15 |
5.8K |
22 |
21/07/21 |
21/07/21 |
ASX - By Stock
|
15
|
5.8K
|
22
|
|
ASX - By Stock
|
PAR |
Likely IND announcement scenarios
|
|
Axlerod
|
15 |
5.8K |
23 |
21/07/21 |
21/07/21 |
ASX - By Stock
|
15
|
5.8K
|
23
|
|
ASX - By Stock
|
PAR |
Re:
Trial
|
|
Axlerod
|
16 |
6.2K |
2 |
20/07/21 |
20/07/21 |
ASX - By Stock
|
16
|
6.2K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
MOZZ Research - First Half 2021
|
|
Axlerod
|
52 |
16K |
10 |
14/07/21 |
14/07/21 |
ASX - By Stock
|
52
|
16K
|
10
|
|
ASX - By Stock
|
PAR |
Re:
Ann: IND QUESTIONS RECEIVED FROM US FDA
|
|
Axlerod
|
389 |
123K |
0 |
27/06/21 |
27/06/21 |
ASX - By Stock
|
389
|
123K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Ann: IND QUESTIONS RECEIVED FROM US FDA
|
|
Axlerod
|
389 |
123K |
3 |
27/06/21 |
27/06/21 |
ASX - By Stock
|
389
|
123K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
Ann: IND QUESTIONS RECEIVED FROM US FDA
|
|
Axlerod
|
389 |
123K |
0 |
25/06/21 |
25/06/21 |
ASX - By Stock
|
389
|
123K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Ann: IND QUESTIONS RECEIVED FROM US FDA
|
|
Axlerod
|
389 |
123K |
1 |
24/06/21 |
24/06/21 |
ASX - By Stock
|
389
|
123K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Ann: IND QUESTIONS RECEIVED FROM US FDA
|
|
Axlerod
|
389 |
123K |
3 |
24/06/21 |
24/06/21 |
ASX - By Stock
|
389
|
123K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
WANTED PARA-008 Trial Participants
|
|
Axlerod
|
127 |
43K |
11 |
24/06/21 |
24/06/21 |
ASX - By Stock
|
127
|
43K
|
11
|
|
ASX - By Stock
|
PAR |
Re:
Ann: IND QUESTIONS RECEIVED FROM US FDA
|
|
Axlerod
|
389 |
123K |
9 |
24/06/21 |
24/06/21 |
ASX - By Stock
|
389
|
123K
|
9
|
|
ASX - By Stock
|
PAR |
Re:
Ann: IND QUESTIONS RECEIVED FROM US FDA
|
|
Axlerod
|
389 |
123K |
2 |
24/06/21 |
24/06/21 |
ASX - By Stock
|
389
|
123K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
WANTED PARA-008 Trial Participants
|
|
Axlerod
|
127 |
43K |
5 |
23/06/21 |
23/06/21 |
ASX - By Stock
|
127
|
43K
|
5
|
|
ASX - By Stock
|
PAR |
Re:
Ann: IND QUESTIONS RECEIVED FROM US FDA
|
|
Axlerod
|
389 |
123K |
2 |
17/06/21 |
17/06/21 |
ASX - By Stock
|
389
|
123K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Ann: IND QUESTIONS RECEIVED FROM US FDA
|
|
Axlerod
|
389 |
123K |
4 |
17/06/21 |
17/06/21 |
ASX - By Stock
|
389
|
123K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
Ann: IND QUESTIONS RECEIVED FROM US FDA
|
|
Axlerod
|
389 |
123K |
5 |
15/06/21 |
15/06/21 |
ASX - By Stock
|
389
|
123K
|
5
|
|
ASX - By Stock
|
PAR |
Re:
Ann: IND QUESTIONS RECEIVED FROM US FDA
|
|
Axlerod
|
389 |
123K |
1 |
28/05/21 |
28/05/21 |
ASX - By Stock
|
389
|
123K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Ann: IND QUESTIONS RECEIVED FROM US FDA
|
|
Axlerod
|
389 |
123K |
0 |
28/05/21 |
28/05/21 |
ASX - By Stock
|
389
|
123K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Ann: IND QUESTIONS RECEIVED FROM US FDA
|
|
Axlerod
|
389 |
123K |
3 |
28/05/21 |
28/05/21 |
ASX - By Stock
|
389
|
123K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
17 |
25/05/21 |
25/05/21 |
ASX - By Stock
|
4.1K
|
1.9M
|
17
|
|
ASX - By Stock
|
PAR |
Re:
Interview 3 with an FDA Process Expert
|
|
Axlerod
|
14 |
5.0K |
20 |
20/05/21 |
20/05/21 |
ASX - By Stock
|
14
|
5.0K
|
20
|
|
ASX - By Stock
|
PAR |
Re:
PAR Clinical Trial - Melbourne
|
|
Axlerod
|
69 |
25K |
19 |
13/05/21 |
13/05/21 |
ASX - By Stock
|
69
|
25K
|
19
|
|
ASX - By Stock
|
PAR |
Re:
Pirate Day Share Price 2021
|
|
Axlerod
|
162 |
62K |
2 |
07/04/21 |
07/04/21 |
ASX - By Stock
|
162
|
62K
|
2
|
|